In a filing, MBX Biosciences Inc revealed its President & CEO Hawryluk P. Kent acquired Company’s shares for reported $0.27 million on Oct 20 ’25. In the deal valued at $13.64 per share,20,000 shares were bought. As a result of this transaction, Hawryluk P. Kent now holds 468,277 shares worth roughly $12.99 million.
Then, Hoerter Steven L. bought 20,000 shares, generating $264,984 in total proceeds. Upon buying the shares at $13.25, the Director now owns 20,000 shares.
Before that, Heron Patrick J bought 666,666 shares. MBX Biosciences Inc shares valued at $11,999,988 were divested by the Director at a price of $18.00 per share. As a result of the transaction, Heron Patrick J now holds 5,219,440 shares, worth roughly $144.84 million.
Goldman initiated its MBX Biosciences Inc [MBX] rating to a Sell in a research note published on December 04, 2025; the price target was $18. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in early November with a ‘”a Buy”‘ rating. Truist began covering MBX with “Buy” recommendation on October 15, 2025.
Price Performance Review of MBX
On Tuesday, MBX Biosciences Inc [NASDAQ:MBX] saw its stock fall -2.22% to $27.75. Over the last five days, the stock has lost -3.24%. MBX Biosciences Inc shares have risen nearly 35.37% since the year began. Nevertheless, the stocks have risen 50.57% over the past one year. While a 52-week high of $34.83 was reached on 11/28/25, a 52-week low of $4.81 was recorded on 04/07/25.
Levels Of Support And Resistance For MBX Stock
The 24-hour chart illustrates a support level at 27.03, which if violated will result in even more drops to 26.31. On the upside, there is a resistance level at 28.48. A further resistance level may holdings at 29.22.
How much short interest is there in MBX Biosciences Inc?
A steep rise in short interest was recorded in MBX Biosciences Inc stocks on 2025-11-28, dropping by -0.48 million shares to a total of 4.1 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 4.58 million shares. There was a decline of -11.7%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 05, 2025 when Mizuho began covering the stock and recommended ‘”an Outperform”‘ rating along with a $38 price target.
